CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, announced today the opening of a new facility, including state-of-the-art Biosafety level 3 (BSL-3) laboratories, in Welwyn Garden City, UK. The BSL-3 laboratories will be dedicated to research, development and drug discovery alliance programmes based on the company’s proprietary in vitro models of viral liver infection, including Hepatitis B. The new facility will additionally comprise BSL-2 laboratories, an engineering laboratory and office space.
- CN Bio FDA collaboration expanded 5th May 2021
- NAFLD vs MAFLD: could a name change impact the progression of liver disease research? 21st April 2021
- Introducing the PhysioMimix™ OOC Multi-Organ Microphysiological System 17th March 2021